Late last week, the FDA approved a new med called Eylea, which is made by Regeneron Pharmaceuticals ( see this), an upstart with board members that include such heavy hitters as former Merck ceo Roy Vagelos and, as of this morning, Marc Tessier-Lavigne, a former executive vp and chief scientific officer at Genentech, who is currently president of Rockefeller University, the medical research institution ( read here).